Index RUT
P/E -
EPS (ttm) -3.97
Insider Own 30.20%
Shs Outstand 97.88M
Perf Week 7.38%
Market Cap 4.36B
Forward P/E -
EPS next Y -3.07
Insider Trans -14.02%
Shs Float 68.32M
Perf Month 31.28%
Income -257.40M
PEG -
EPS next Q -0.72
Inst Own 68.23%
Short Float 13.53%
Perf Quarter 87.93%
Sales 0.00M
P/S -
EPS this Y 23.78%
Inst Trans -2.79%
Short Ratio 7.40
Perf Half Y 148.77%
Book/sh 5.49
P/B 8.11
EPS next Y -1.91%
ROA -63.48%
Short Interest 9.24M
Perf Year 317.34%
Cash/sh 4.63
P/C 9.61
EPS next 5Y -
ROE -71.50%
52W Range 6.40 - 45.46
Perf YTD 234.81%
Dividend Est. -
P/FCF -
EPS past 5Y -106.26%
ROI -51.49%
52W High -2.03%
Beta 1.03
Dividend TTM -
Quick Ratio 21.83
Sales past 5Y 0.00%
Gross Margin -
52W Low 595.78%
ATR (14) 2.05
Dividend Ex-Date -
Current Ratio 21.83
EPS Y/Y TTM -18.88%
Oper. Margin 0.00%
RSI (14) 68.11
Volatility 4.63% 5.35%
Employees 141
Debt/Eq 0.06
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 46.30
Option/Short Yes / Yes
LT Debt/Eq 0.05
EPS Q/Q -3.25%
Payout -
Rel Volume 0.76
Prev Close 42.70
Sales Surprise -100.00%
EPS Surprise -1.25%
Sales Q/Q -
Earnings May 02 AMC
Avg Volume 1.25M
Price 44.53
SMA20 12.92%
SMA50 27.52%
SMA200 97.91%
Trades
Volume 954,919
Change 4.29%
Date
Action
Analyst
Rating Change
Price Target Change
May-21-24 Reiterated
Chardan Capital Markets
Buy
$31 → $42
Apr-30-24 Initiated
Morgan Stanley
Overweight
$40
Feb-20-24 Initiated
H.C. Wainwright
Buy
$36
Feb-27-23 Upgrade
Raymond James
Outperform → Strong Buy
$16 → $27
Feb-15-23 Initiated
Oppenheimer
Outperform
$34
Jan-26-23 Initiated
Guggenheim
Buy
$33
Jul-20-22 Initiated
Chardan Capital Markets
Buy
$17
Jul-12-22 Initiated
Raymond James
Outperform
$15
Oct-12-20 Initiated
Stifel
Buy
$29
Oct-12-20 Initiated
Piper Sandler
Overweight
$34
Oct-12-20 Initiated
JP Morgan
Overweight
$27
Oct-12-20 Initiated
Jefferies
Buy
$47
Show Previous Ratings
Jul-18-24 12:00PM
Jul-12-24 08:50AM
Jun-24-24 07:30AM
Jun-13-24 04:40PM
Jun-04-24 06:00AM
07:30AM
Loading…
May-30-24 07:30AM
May-28-24 07:30AM
May-21-24 08:39PM
12:27PM
07:17AM
May-20-24 05:53PM
04:27PM
04:07PM
(Investor's Business Daily)
04:01PM
11:22AM
09:40AM
Loading…
09:40AM
09:12AM
08:02AM
07:47AM
07:36AM
06:30AM
May-19-24 08:00AM
May-04-24 05:31AM
May-02-24 11:52PM
04:10PM
Apr-30-24 07:32AM
Mar-27-24 04:05PM
08:30AM
Mar-25-24 12:28PM
(Associated Press Finance) -7.72%
07:30AM
07:30AM
Loading…
Mar-13-24 07:30AM
Mar-07-24 01:19PM
Mar-05-24 10:53AM
07:30AM
Mar-02-24 12:00AM
Feb-29-24 03:02AM
Feb-14-24 04:15PM
Feb-01-24 07:30AM
Jan-26-24 11:01PM
Jan-22-24 10:14PM
Jan-12-24 01:12PM
Jan-11-24 04:05PM
Jan-05-24 09:02AM
07:30AM
Jan-04-24 10:46PM
04:37PM
12:39PM
Jan-03-24 04:25PM
02:46PM
(The Wall Street Journal)
02:01PM
(The Wall Street Journal)
08:19AM
06:30AM
Jan-02-24 04:05PM
Nov-13-23 06:59PM
Nov-07-23 07:30AM
Oct-31-23 05:36AM
01:11AM
Oct-30-23 07:30AM
Sep-28-23 07:30AM
Sep-20-23 04:05PM
Sep-15-23 01:52PM
Sep-14-23 01:22PM
Sep-05-23 07:30AM
Aug-28-23 10:22AM
Aug-03-23 07:30AM
Jun-16-23 08:46AM
Jun-01-23 07:30AM
May-25-23 07:30AM
May-17-23 11:25AM
07:30AM
May-11-23 07:30AM
May-03-23 07:35AM
May-02-23 04:46PM
Mar-23-23 07:30AM
Mar-20-23 07:30AM
Mar-07-23 07:30AM
Mar-02-23 07:30AM
Mar-01-23 09:00AM
(Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM
Feb-05-23 05:03AM
Jan-19-23 08:23AM
Jan-18-23 08:49AM
Jan-10-23 12:00PM
Jan-03-23 07:30AM
Dec-16-22 09:55AM
Dec-09-22 09:55AM
Dec-08-22 08:10AM
Nov-30-22 09:55AM
Nov-03-22 07:30AM
Nov-02-22 07:30AM
Oct-31-22 07:30AM
Oct-12-22 06:45AM
(American City Business Journals)
Oct-11-22 04:10PM
Sep-27-22 07:30AM
Sep-12-22 07:00AM
Sep-06-22 04:30PM
(GlobeNewswire) +5.32%
+18.25%
07:01AM
07:00AM
Aug-29-22 07:30AM
Aug-10-22 07:30AM
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HIGH SUSANNA GATTI Chief Operating Officer Jun 24 '24 Option Exercise 5.54 10,163 56,303 158,955 Jun 24 08:41 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 24 '24 Sale 35.33 10,163 359,059 148,792 Jun 24 08:41 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 21 '24 Option Exercise 5.54 29,787 165,020 178,579 Jun 24 08:41 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 21 '24 Sale 35.01 29,787 1,042,843 148,792 Jun 24 08:41 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 12 '24 Option Exercise 5.54 40,000 221,600 188,792 Jun 13 09:45 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 12 '24 Sale 33.36 40,000 1,334,201 148,792 Jun 13 09:45 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 11 '24 Sale 31.23 5,270 164,582 148,792 Jun 11 07:34 PM Farwell Wildon Chief Medical Officer Jun 11 '24 Sale 31.27 2,636 82,428 145,543 Jun 11 07:41 PM Beskrovnaya Oxana Chief Scientific Officer Jun 11 '24 Sale 31.34 2,136 66,942 147,511 Jun 11 07:42 PM McNeill Jonathan Chief Business Officer Jun 11 '24 Sale 31.34 1,823 57,133 134,811 Jun 11 07:34 PM Scalzo Richard William SVP, Head of Finance & Admin. Jun 11 '24 Sale 31.34 1,331 41,714 113,774 Jun 11 07:28 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 10 '24 Option Exercise 5.54 80,000 443,200 234,062 Jun 11 07:34 PM HIGH SUSANNA GATTI Chief Operating Officer Jun 10 '24 Sale 30.24 80,000 2,419,200 154,062 Jun 11 07:34 PM Scalzo Richard William SVP, Head of Finance & Admin. Jun 10 '24 Sale 30.23 1,590 48,066 115,105 Jun 11 07:28 PM Beskrovnaya Oxana Chief Scientific Officer May 20 '24 Option Exercise 1.03 30,426 31,339 180,073 May 22 09:01 PM Beskrovnaya Oxana Chief Scientific Officer May 20 '24 Sale 32.96 30,426 1,002,751 149,647 May 22 09:01 PM McNeill Jonathan Chief Business Officer May 16 '24 Sale 28.27 2,774 78,420 136,634 May 17 09:03 PM HIGH SUSANNA GATTI Chief Operating Officer May 16 '24 Sale 28.27 2,738 77,402 154,062 May 17 09:05 PM Beskrovnaya Oxana Chief Scientific Officer May 16 '24 Sale 28.27 2,705 76,469 149,647 May 17 09:07 PM Scalzo Richard William SVP, Head of Finance & Admin. May 16 '24 Sale 28.27 2,588 73,162 116,695 May 17 09:04 PM Farwell Wildon Chief Medical Officer May 16 '24 Sale 28.27 2,381 67,310 148,179 May 17 09:06 PM Farwell Wildon Chief Medical Officer Mar 12 '24 Sale 25.58 1,030 26,347 150,560 Mar 12 09:58 PM Brumm Joshua T CEO & President Mar 11 '24 Option Exercise 5.54 50,000 277,000 604,385 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 11 '24 Option Exercise 5.54 17,825 98,750 159,009 Mar 13 06:04 AM Brumm Joshua T CEO & President Mar 11 '24 Sale 25.67 66,387 1,704,142 537,998 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 11 '24 Sale 25.50 19,601 499,842 139,408 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 11 '24 Sale 25.28 2,672 67,542 119,283 Mar 12 09:57 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 11 '24 Sale 25.70 2,292 58,904 156,800 Mar 13 06:04 AM Beskrovnaya Oxana Chief Scientific Officer Mar 11 '24 Sale 25.70 2,081 53,482 152,352 Mar 12 09:42 PM Farwell Wildon Chief Medical Officer Mar 11 '24 Sale 25.70 1,585 40,734 151,590 Mar 12 09:58 PM Brumm Joshua T CEO & President Mar 08 '24 Option Exercise 5.54 363,343 2,012,920 917,728 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 08 '24 Option Exercise 5.54 90,000 498,600 231,184 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 08 '24 Option Exercise 5.54 86,252 477,836 208,207 Mar 12 09:57 PM Brumm Joshua T CEO & President Mar 08 '24 Sale 25.93 363,343 9,421,634 554,385 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 08 '24 Sale 26.24 90,000 2,361,531 141,184 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 08 '24 Sale 26.22 86,252 2,261,465 121,955 Mar 12 09:57 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 08 '24 Sale 26.67 27,199 725,344 159,092 Mar 13 06:04 AM Farwell Wildon Chief Medical Officer Mar 07 '24 Sale 25.86 9,921 256,585 153,175 Mar 11 09:52 PM Brumm Joshua T CEO & President Mar 07 '24 Sale 25.85 9,086 234,873 554,385 Mar 11 09:57 PM McNeill Jonathan Chief Business Officer Mar 07 '24 Sale 25.85 2,434 62,919 141,184 Mar 11 09:50 PM Beskrovnaya Oxana Chief Scientific Officer Mar 07 '24 Sale 25.85 2,373 61,342 154,433 Mar 11 09:56 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 07 '24 Sale 25.85 2,273 58,757 121,955 Mar 11 09:45 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 07 '24 Sale 25.85 1,591 41,127 186,291 Mar 11 09:56 PM Brumm Joshua T CEO & President Mar 01 '24 Option Exercise 5.54 94,480 523,419 657,951 Mar 01 09:38 PM McNeill Jonathan Chief Business Officer Mar 01 '24 Option Exercise 0.73 24,260 17,710 167,878 Mar 01 09:37 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 01 '24 Option Exercise 1.03 9,311 9,590 133,539 Mar 01 09:37 PM Brumm Joshua T CEO & President Mar 01 '24 Sale 29.04 94,480 2,743,718 563,471 Mar 01 09:38 PM Rhodes Jason P Director Mar 01 '24 Sale 30.05 46,534 1,398,347 847,388 Mar 05 05:08 PM Atlas Venture Opportunity Fund 10% Owner Mar 01 '24 Sale 30.05 29,435 884,522 1,458,691 Mar 05 05:07 PM McNeill Jonathan Chief Business Officer Mar 01 '24 Sale 28.63 24,260 694,495 143,618 Mar 01 09:37 PM Atlas Venture Opportunity Fund 10% Owner Mar 01 '24 Sale 30.05 17,099 513,825 847,388 Mar 05 05:07 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 01 '24 Sale 28.25 9,311 262,999 124,228 Mar 01 09:37 PM Brumm Joshua T CEO & President Feb 29 '24 Option Exercise 5.54 5,520 30,581 568,991 Mar 01 09:38 PM Scalzo Richard William SVP, Head of Finance & Admin. Feb 29 '24 Option Exercise 1.03 3,429 3,532 127,657 Mar 01 09:37 PM McNeill Jonathan Chief Business Officer Feb 29 '24 Option Exercise 0.73 4,268 3,116 147,886 Mar 01 09:37 PM Brumm Joshua T CEO & President Feb 29 '24 Sale 27.50 5,520 151,800 563,471 Mar 01 09:38 PM McNeill Jonathan Chief Business Officer Feb 29 '24 Sale 27.50 4,268 117,370 143,618 Mar 01 09:37 PM Scalzo Richard William SVP, Head of Finance & Admin. Feb 29 '24 Sale 27.50 3,429 94,298 124,228 Mar 01 09:37 PM Rhodes Jason P Director Feb 28 '24 Sale 24.84 190,920 4,741,804 864,487 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 28 '24 Sale 24.84 154,674 3,841,576 5,698,091 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 28 '24 Sale 24.84 36,246 900,228 864,487 Feb 28 07:13 PM Rhodes Jason P Director Feb 27 '24 Sale 24.41 368,699 8,998,426 877,806 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 27 '24 Sale 24.41 298,702 7,290,088 5,852,765 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 27 '24 Sale 24.41 69,997 1,708,338 877,806 Feb 28 07:13 PM Rhodes Jason P Director Feb 26 '24 Sale 23.72 248,219 5,886,673 903,527 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 26 '24 Sale 23.72 201,095 4,769,096 6,151,467 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 26 '24 Sale 23.72 47,124 1,117,577 903,527 Feb 28 07:13 PM Rhodes Jason P Director Feb 23 '24 Sale 22.70 196,928 4,470,266 920,843 Feb 23 06:59 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 23 '24 Sale 22.70 159,542 3,621,603 6,352,562 Feb 23 06:58 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 23 '24 Sale 22.70 37,386 848,662 920,843 Feb 23 06:58 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 22 '24 Sale 22.66 119,360 2,704,698 6,512,104 Feb 23 06:58 PM Rhodes Jason P Director Feb 22 '24 Sale 22.66 119,360 2,704,698 6,512,104 Feb 23 06:59 PM Rhodes Jason P Director Feb 21 '24 Sale 22.57 184,501 4,164,817 6,631,464 Feb 23 06:59 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 21 '24 Sale 22.57 184,501 4,164,817 6,631,464 Feb 23 06:58 PM Rhodes Jason P Director Feb 20 '24 Sale 22.72 169,539 3,852,653 6,815,965 Feb 20 06:36 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 20 '24 Sale 22.72 169,539 3,852,653 6,815,965 Feb 20 06:35 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 16 '24 Sale 23.14 162,707 3,765,040 6,985,504 Feb 20 06:35 PM Rhodes Jason P Director Feb 16 '24 Sale 23.14 162,707 3,765,040 6,985,504 Feb 20 06:36 PM Rhodes Jason P Director Feb 15 '24 Sale 23.89 177,906 4,249,600 7,148,211 Feb 20 06:36 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 15 '24 Sale 23.89 177,906 4,249,600 7,148,211 Feb 20 06:35 PM Farwell Wildon Chief Medical Officer Feb 12 '24 Sale 25.07 5,493 137,710 163,503 Feb 14 04:27 PM McNeill Jonathan Chief Business Officer Jan 26 '24 Option Exercise 0.73 20,000 14,600 163,618 Jan 26 07:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 26 '24 Option Exercise 1.03 13,000 13,390 137,228 Jan 26 07:47 PM McNeill Jonathan Chief Business Officer Jan 26 '24 Sale 24.53 20,000 490,510 143,618 Jan 26 07:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 26 '24 Sale 24.34 13,000 316,420 124,228 Jan 26 07:47 PM Farwell Wildon Chief Medical Officer Jan 26 '24 Sale 25.00 100 2,500 168,996 Jan 26 07:49 PM Kersten Dirk Director Jan 09 '24 Buy 17.50 1,714,285 29,999,988 6,416,793 Jan 11 04:31 PM Brumm Joshua T CEO & President Jan 04 '24 Option Exercise 5.16 218,536 1,127,092 803,507 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 04 '24 Option Exercise 1.03 22,674 23,354 199,259 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 04 '24 Option Exercise 0.73 2,009 1,467 145,627 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 04 '24 Sale 18.51 218,536 4,045,958 584,971 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 04 '24 Sale 18.13 42,453 769,673 156,806 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 04 '24 Sale 18.04 2,009 36,242 143,618 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 03 '24 Option Exercise 1.03 51,183 52,718 636,154 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 03 '24 Option Exercise 1.03 45,326 46,686 221,911 Jan 04 09:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 03 '24 Option Exercise 1.03 13,000 13,390 137,228 Jan 04 09:46 PM McNeill Jonathan Chief Business Officer Jan 03 '24 Option Exercise 0.73 17,991 13,133 161,609 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 03 '24 Sale 19.28 51,183 986,957 584,971 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 03 '24 Sale 18.98 45,326 860,313 176,585 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 03 '24 Sale 18.74 17,991 337,062 143,618 Jan 04 09:47 PM
Index -
P/E -
EPS (ttm) -2.57
Insider Own 43.84%
Shs Outstand 27.61M
Perf Week 4.12%
Market Cap 37.28M
Forward P/E -
EPS next Y -0.94
Insider Trans 3.08%
Shs Float 20.73M
Perf Month 10.73%
Income -70.96M
PEG -
EPS next Q -0.23
Inst Own 11.21%
Short Float 0.70%
Perf Quarter 0.00%
Sales 0.00M
P/S -
EPS this Y 49.82%
Inst Trans -4.43%
Short Ratio 0.53
Perf Half Y 57.81%
Book/sh 0.75
P/B 1.35
EPS next Y 32.62%
ROA -73.11%
Short Interest 0.14M
Perf Year -64.18%
Cash/sh 0.92
P/C 1.10
EPS next 5Y -
ROE -128.37%
52W Range 0.49 - 2.94
Perf YTD 83.64%
Dividend Est. -
P/FCF -
EPS past 5Y -44.91%
ROI -211.02%
52W High -65.65%
Beta -0.07
Dividend TTM -
Quick Ratio 2.19
Sales past 5Y 0.00%
Gross Margin -
52W Low 106.12%
ATR (14) 0.07
Dividend Ex-Date -
Current Ratio 2.19
EPS Y/Y TTM 21.31%
Oper. Margin 0.00%
RSI (14) 53.70
Volatility 8.15% 7.22%
Employees 73
Debt/Eq 0.35
Sales Y/Y TTM -
Profit Margin -
Recom 1.50
Target Price 5.50
Option/Short No / Yes
LT Debt/Eq 0.31
EPS Q/Q 25.34%
Payout -
Rel Volume 0.33
Prev Close 0.96
Sales Surprise -100.00%
EPS Surprise -463.64%
Sales Q/Q -
Earnings May 14 BMO
Avg Volume 273.00K
Price 1.01
SMA20 5.49%
SMA50 0.61%
SMA200 -3.16%
Trades
Volume 88,769
Change 5.33%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated
Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated
H.C. Wainwright
Buy
$36
Nov-16-21 Initiated
Raymond James
Outperform
$31
Nov-16-21 Initiated
Morgan Stanley
Overweight
$32
Nov-16-21 Initiated
Guggenheim
Buy
$40
Nov-16-21 Initiated
Cowen
Outperform
Jun-13-24 04:05PM
May-29-24 06:05AM
(Pharmaceutical Technology)
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
10:53PM
Loading…
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
(GlobeNewswire) +5.60%
+7.42%
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
04:01PM
Loading…
Nov-09-23 04:01PM
(GlobeNewswire) -13.04%
-10.63%
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
07:30AM
Loading…
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 733 469 2,019,563 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 267 171 734,546 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 1,540 1,278 2,020,296 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 560 465 734,813 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 1,566 1,362 2,021,836 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 569 495 735,373 Jan 16 06:16 PM
Index RUT
P/E -
EPS (ttm) -0.74
Insider Own 62.81%
Shs Outstand 40.10M
Perf Week 5.42%
Market Cap 509.83M
Forward P/E -
EPS next Y -1.47
Insider Trans -0.27%
Shs Float 15.23M
Perf Month -0.80%
Income -29.59M
PEG -
EPS next Q -0.29
Inst Own 39.72%
Short Float 10.39%
Perf Quarter 19.02%
Sales 0.00M
P/S -
EPS this Y -48.03%
Inst Trans -
Short Ratio 16.62
Perf Half Y 35.77%
Book/sh 6.55
P/B 1.90
EPS next Y -27.47%
ROA -10.53%
Short Interest 1.58M
Perf Year 103.76%
Cash/sh 6.42
P/C 1.94
EPS next 5Y -
ROE -10.84%
52W Range 5.41 - 16.94
Perf YTD 13.49%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -11.10%
52W High -26.51%
Beta 2.89
Dividend TTM -
Quick Ratio 66.10
Sales past 5Y 0.00%
Gross Margin -
52W Low 130.13%
ATR (14) 0.64
Dividend Ex-Date -
Current Ratio 66.10
EPS Y/Y TTM 32.17%
Oper. Margin 0.00%
RSI (14) 49.39
Volatility 4.63% 4.98%
Employees 30
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 1.83
Target Price 17.00
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 50.98%
Payout -
Rel Volume 0.52
Prev Close 12.56
Sales Surprise -
EPS Surprise 35.50%
Sales Q/Q -
Earnings May 15 BMO
Avg Volume 95.19K
Price 12.45
SMA20 0.72%
SMA50 -4.80%
SMA200 20.92%
Trades
Volume 49,178
Change -0.88%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-18-24 Initiated
Stifel
Buy
$23
Jun-07-24 Initiated
Raymond James
Outperform
$18
Dec-16-22 Downgrade
Jefferies
Buy → Hold
$30 → $3.60
Dec-15-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$5
Oct-10-22 Initiated
Morgan Stanley
Overweight
$34
Oct-10-22 Initiated
Jefferies
Buy
$30
Oct-10-22 Initiated
Cowen
Outperform
May-28-24 04:05PM
May-20-24 04:36PM
May-15-24 12:52PM
08:05AM
May-10-24 07:02PM
07:00PM
Loading…
Apr-15-24 07:00PM
Mar-28-24 08:30AM
Mar-26-24 09:02PM
01:53PM
08:05AM
Feb-26-24 04:00PM
Jan-04-24 08:00AM
Dec-29-23 12:00PM
Dec-08-23 01:05PM
Nov-09-23 09:30AM
08:30AM
Loading…
08:30AM
Oct-31-23 08:30AM
Aug-31-23 08:30AM
Aug-10-23 08:10AM
Jul-26-23 09:40AM
Jul-25-23 08:30AM
Jun-09-23 08:04AM
May-24-23 11:02AM
May-11-23 05:00PM
Mar-29-23 08:05AM
Dec-23-22 06:32AM
Dec-22-22 05:41AM
(American City Business Journals)
Dec-15-22 10:10AM
09:53AM
08:49AM
08:22AM
Loading…
08:22AM
07:00AM
Nov-21-22 04:05PM
Nov-09-22 04:15PM
Nov-02-22 08:01AM
(Investor's Business Daily) -6.14%
Sep-19-22 04:10PM
Sep-15-22 11:41AM
07:58AM
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Person Julie CHIEF ADMINISTRATIVE OFFICER Jun 26 '24 Option Exercise 4.20 10,000 42,000 10,000 Jun 28 04:51 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Jun 26 '24 Sale 12.46 10,000 124,569 0 Jun 28 04:51 PM Dittman Jennifer Chief Development Oper Officer Jun 07 '24 Sale 14.17 494 7,000 0 Jun 10 04:26 PM Dittman Jennifer Chief Development Oper Officer May 20 '24 Sale 14.00 1,042 14,588 0 May 22 04:36 PM Dittman Jennifer Chief Development Oper Officer May 16 '24 Sale 14.04 23,578 331,066 0 May 20 04:33 PM Holles Natalie C. CEO May 09 '24 Option Exercise 4.20 20,222 84,932 1,239,058 May 10 04:04 PM Holles Natalie C. CEO May 09 '24 Sale 12.18 20,222 246,300 1,218,836 May 10 04:04 PM Holles Natalie C. CEO Apr 11 '24 Option Exercise 4.20 13,558 56,944 1,232,394 Apr 15 04:14 PM Holles Natalie C. CEO Apr 11 '24 Sale 12.19 13,558 165,214 1,218,836 Apr 15 04:14 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Apr 04 '24 Option Exercise 4.20 1,107 4,649 1,107 Apr 08 05:21 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Apr 04 '24 Sale 10.00 1,107 11,070 0 Apr 08 05:21 PM Person Julie Chief Administrative Officer Dec 05 '23 Option Exercise 4.20 12,863 54,025 12,863 Dec 07 04:04 PM Conner Edward R. Chief Medical Officer Dec 05 '23 Option Exercise 4.20 4,790 20,118 4,790 Dec 07 04:03 PM Person Julie Chief Administrative Officer Dec 05 '23 Sale 10.30 12,863 132,484 0 Dec 07 04:04 PM Conner Edward R. Chief Medical Officer Dec 05 '23 Sale 10.03 4,790 48,062 0 Dec 07 04:03 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite